Who are Ringer lactate (RL)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Plasma-lyte (dynamic group), Ringer-acetat, Enriched Ringer's lactate solution, Lactated Ringer, Lactated Ringer's Solution, Plasma-lyte (static group).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ringer-lactate-rl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ringer lactate (RL) — Competitive Intelligence Brief

Ringer lactate (RL) (Ringer lactate (RL)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Crystalloid intravenous fluid. Area: Critical Care / Fluid Resuscitation.

marketed Crystalloid intravenous fluid Critical Care / Fluid Resuscitation Small molecule Live · refreshed every 30 min

Target snapshot

Ringer lactate (RL) (Ringer lactate (RL)) — Fundación Cardioinfantil Instituto de Cardiología. Ringer lactate is a crystalloid intravenous fluid that replaces lost body fluids and electrolytes to restore intravascular volume and maintain hemodynamic stability.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Ringer lactate (RL) TARGET	Ringer lactate (RL)	Fundación Cardioinfantil Instituto de Cardiología	marketed	Crystalloid intravenous fluid
Plasma-lyte (dynamic group)	Plasma-lyte (dynamic group)	Algemeen Ziekenhuis Maria Middelares	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution
Ringer-acetat	Ringer-acetat	Rigshospitalet, Denmark	marketed	Crystalloid intravenous fluid
Enriched Ringer's lactate solution	Enriched Ringer's lactate solution	Scientific Institute San Raffaele	marketed	Crystalloid intravenous fluid
Lactated Ringer	Lactated Ringer	Fayoum University Hospital	marketed	Crystalloid intravenous fluid
Lactated Ringer's Solution	Lactated Ringer's Solution	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Crystalloid intravenous fluid
Plasma-lyte (static group)	Plasma-lyte (static group)	Algemeen Ziekenhuis Maria Middelares	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Crystalloid intravenous fluid class)

Fayoum University Hospital · 1 drug in this class
Federal University of Juiz de Fora · 1 drug in this class
Fundación Cardioinfantil Instituto de Cardiología · 1 drug in this class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Nationwide Children's Hospital · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class
Scientific Institute San Raffaele · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ringer lactate (RL) — Competitive Intelligence Brief. https://druglandscape.com/ci/ringer-lactate-rl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab